Pamisel Launches Full-Scale CDMO Business for Stem Cell Therapy Products

[Asia Economy Reporter Hyunseok Yoo] Pharmicell announced on the 15th that it will officially enter the contract development and manufacturing organization (CDMO) business based on its know-how in commercializing stem cell therapeutics.

With the recent enforcement of the 'Advanced Regenerative Bio Act,' inquiries and interest in stem cell clinical research have surged, prompting the company to advance one step further from its existing contract manufacturing organization (CMO) business to secure future growth engines.

CDMO is a business combining contract manufacturing (CMO) and contract development (CDO), meaning it goes beyond simply producing clinical trial and commercial drugs on consignment. It provides services that assist the entire new drug development process?from cell line development to clinical trials and market approval?through a collaborative structure with partner companies. Notably, once a partnership is established, it is difficult to replace, allowing the contracted company to sustain long-term business.

A company official stated, “Pharmicell possesses industry-leading stem cell therapeutic development technology and systematic CDMO infrastructure, including pharmaceutical manufacturing and quality management standard (GMP) production facilities certified by the Ministry of Food and Drug Safety. We look forward to expanding partnerships with bio companies interested in commercializing stem cell therapeutics but facing difficulties due to lack of facilities and experience.”

This content was produced with the assistance of AI translation services.